- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
EU Authorizes Second Pegfilgrastim Biosimilar, Pelgraz
The European Union (EU) today authorized its second pegfilgrastim biosimilar, referenced on Neulasta. The product, to be sold as Pelgraz, is indicated to reduce the duration of neutropenia, as well as the incidence of febrile neutropenia for adult patients undergoing cytotoxic chemotherapy.
The European Union (EU) today authorized its second pegfilgrastim biosimilar, referenced on Neulasta. The product, to be sold as Pelgraz, is indicated to reduce the duration of neutropenia, as well as the incidence of febrile neutropenia for adult patients undergoing cytotoxic chemotherapy.
Accord Healthcare, the developer of the biosimilar, has said that the first countries will launch the product immediately on receipt of their marketing authorization and appropriate national price and reimbursement activities, which will potentially “make Accord the first to market a biosimilar pegfilgrastim in Europe.” Of note, Accord has said that Pelgraz is the only licensed biosimilar treatment in the EU that has phase 3 clinical data in addition to phase 1 as part of its efficacy and safety profile.
“This approval builds on our established expertise and extensive oncology treatment portfolio. We are committed to ensuring that Pelgraz will be made available as each country concludes its regulatory process. We anticipate being first out of production and into the healthcare professional’s hands in most European markets,” said Paul Tredwell, Accord vice president of Specialty Brands, Europe/Middle East/North Africa Regions.
The approval was based on the clinical development program for Pelgraz, which supported its biosimilarity with Neulasta. “This is an important development for the thousands of cancer patients in Europe undergoing chemotherapy who will have greater access to this vital medicine in their cancer treatment journey,” said Paul Cornes, MD, consultant oncologist, Bristol. “Pegfilgrastim is one dose per cycle administration, which may reduce the need for white blood cell count monitoring and patients avoid the potential worry of daily injections.”
This marks the second pegfilgrastim biosimilar approved in Europe in the same week; just yesterday the European Commission granted a marketing authorization for Coherus’ CHS-1701, a pegfilgrastim biosimilar to be sold as Udenyca.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
What Stands in the Way of Biosimilar Use Across MENA Countries?
May 21st 2025Despite the clear promise of cost savings and expanded access, the path to integrating generics and biosimilars across the Middle East and North Africa (MENA) region is tangled in a web of distrust, inconsistent policies, and deep-rooted cultural preferences for branded drugs.
